Eli Lilly and Company (BVL:LLY)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 2.76T +3.5% |
| Revenue (ttm) | 219.28B +44.7% |
| Net Income | 69.44B +94.9% |
| EPS | 77.21 +96.0% |
| Shares Out | n/a |
| PE Ratio | 39.81 |
| Forward PE | 25.59 |
| Dividend | 21.75 (2.45%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 2 |
| Average Volume | 0 |
| Open | 889.50 |
| Previous Close | 999.40 |
| Day's Range | 889.50 - 889.50 |
| 52-Week Range | 632.70 - 1,096.00 |
| Beta | n/a |
| RSI | 17.07 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Lilly and Novo Show How AI Is Rewiring Big Pharma
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug ...
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th...
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
Why Eli Lilly Is Buying Centessa for $7.8 Billion
Bloomberg Intelligence's Sam Fazeli discusses Eli Lilly's $7.8 billion acquisition of Centessa, marking the company's entry into the sleep disorder drug market. He speaks on "Bloomberg Open Interest.
Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, "predictable" monthly prices. Eligible patients can c...
Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion
Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial $6.3 billion in a deal that expands the drugmaker's neuroscience portfolio and capabilities into sleep medici...
Eli Lilly to buy Centessa Pharma in $6.3 billion deal
Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal worth about $6.3 billion to advance treatments for sleep-wake disorders.
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lil...
Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.
Technical indicators for Pfizer and GSK have turned bullish.
Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership
Eli Lilly is doubling down on AI drug development with its latest deal.
Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.
Lilly will obtain exclusive rights to sell treatments discovered using InSilico's Pharma.AI model.
Eli Lilly Makes $2.75 Billion Bet on AI-Powered Drug Discovery
Pharmaceutical titan Eli Lilly wants to bring medications developed with AI to market. To that end, the company has struck a $2.75 billion deal, announced Sunday (March 29), with Hong Kong-based Insil...
Eli Lilly inks $2.75B AI deal with Insilico, bets on China biotech
Global pharmaceutical major Eli Lilly has signed a drug discovery agreement with Insilico Medicine that could be worth up to $2.75 billion. The deal underscores the growing role of artificial intellig...
Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports
Eli Lilly wants the UK to regularly raise NHS drug prices and phase out a multi-billion-pound rebate scheme if it is to resume investment, its international businesses president Patrik Jonsson told ...
Eli Lilly, InSilico Strike AI Drug Discovery Deal
Hong Kong-listed InSilico sad the deal could be valued at as much as $2.75 billion.
Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery
Insilico Medicine said on Sunday it is partnering with Eli Lilly in a deal worth up to $2.75 billion, expanding an existing collaboration on AI-powered drug discovery.
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs. The two companies have worked together since 2023.
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says
Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine , which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also pu...
Lilly's eczema drug shows durable long-term response in late-stage study
Eli Lilly said on Friday that its eczema drug showed durable results in a late-stage post-marketing study, such as relief from persistent itch for up to four years in patients with the skin condit...
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin clearanc...
The market for weight loss drugs is exploding and patients may have several new options in coming years—here's a look, in charts
The market for weight loss drugs is exploding and patients may have several new options in coming years.
What's Going On With Eli Lilly On Monday?
More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions.
U.S. executives, from Apple to Eli Lilly, revamp their push into the world's second-largest economy at the China Development Forum
Household names were among the more than 30 U.S. corporate executives who joined the China Development Forum in Beijing over the weekend. Fresh off a recovery in Apple iPhone sales in China, CEO Tim C...